---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002987"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:37:00.395875+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Profound Medical Q1 2025 revenue $2.6M (+82% YoY); net loss $10.7M vs $6.6M

## Summary
- Revenue $2.6M, up 82% from $1.4M in Q1 2024; gross margin 71% vs 60%.
- Net loss $10.7M ($0.36/share) vs $6.6M ($0.27/share) a year ago.
- Operating expenses $13.0M, up from $8.7M on commercial expansion and R&D.
- Cash $46.4M at March 31; 30,053,142 shares outstanding as of May 8.
- Urology APC Level 7 codes effective 2025; TULSA-AI BPH module and TULSA+ planned H2 2025.

## SEC filing metadata
- accession: 0001171843-25-002987
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184325002987/0001171843-25-002987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184325002987/f8k_050825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002987
- JSON: https://secwatch.observer/filing/0001171843-25-002987.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.